Michael H. Goldstein Buys 10,000 Shares of Ocular Therapeutix Inc (OCUL) Stock

Ocular Therapeutix Inc (NASDAQ:OCUL) insider Michael H. Goldstein bought 10,000 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average price of $4.15 per share, with a total value of $41,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

NASDAQ OCUL opened at $4.10 on Wednesday. The stock has a market capitalization of $173.92 million, a P/E ratio of -2.61 and a beta of 1.89. The company has a debt-to-equity ratio of 0.69, a current ratio of 6.14 and a quick ratio of 6.11. Ocular Therapeutix Inc has a twelve month low of $3.46 and a twelve month high of $8.28.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.05). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.45 million. Ocular Therapeutix had a negative return on equity of 136.09% and a negative net margin of 3,013.97%. As a group, sell-side analysts anticipate that Ocular Therapeutix Inc will post -1.58 earnings per share for the current year.

Several equities research analysts recently weighed in on OCUL shares. Cantor Fitzgerald increased their target price on shares of Ocular Therapeutix from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, December 3rd. HC Wainwright set a $12.00 target price on shares of Ocular Therapeutix and gave the company a “buy” rating in a research note on Friday, January 11th. BidaskClub upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Sunday, December 2nd. Cowen reiterated a “buy” rating and issued a $13.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 4th. Finally, ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $12.61.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in Ocular Therapeutix by 5.2% during the fourth quarter. Bank of New York Mellon Corp now owns 99,190 shares of the biopharmaceutical company’s stock worth $395,000 after purchasing an additional 4,896 shares during the period. Wells Fargo & Company MN lifted its stake in Ocular Therapeutix by 37.0% during the third quarter. Wells Fargo & Company MN now owns 45,046 shares of the biopharmaceutical company’s stock worth $310,000 after purchasing an additional 12,170 shares during the period. JGP Global Gestao de Recursos Ltda. bought a new position in Ocular Therapeutix during the fourth quarter worth about $50,000. Teachers Advisors LLC lifted its stake in Ocular Therapeutix by 24.1% during the third quarter. Teachers Advisors LLC now owns 67,202 shares of the biopharmaceutical company’s stock worth $462,000 after purchasing an additional 13,061 shares during the period. Finally, Northern Trust Corp lifted its stake in Ocular Therapeutix by 3.7% during the fourth quarter. Northern Trust Corp now owns 403,442 shares of the biopharmaceutical company’s stock worth $1,606,000 after purchasing an additional 14,493 shares during the period. Hedge funds and other institutional investors own 50.50% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Michael H. Goldstein Buys 10,000 Shares of Ocular Therapeutix Inc (OCUL) Stock” was reported by WKRB News and is the property of of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.wkrb13.com/2019/03/20/michael-h-goldstein-buys-10000-shares-of-ocular-therapeutix-inc-ocul-stock.html.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

See Also: How to Use the New Google Finance Tool

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.